Telehealth company Talkiatry has partnered with Biogen to expand its support service for women who develop postpartum depression (PPD) in a move that could help drive uptake of the latter's
Sage Therapeutics has said it will cut its headcount by 40% in the wake of the narrower-than-hoped approval of its flagship antidepressant Zurzuvae by the FDA, with two of
Sage Therapeutics is facing the possibility of job losses and other cutbacks in the wake of the narrower-than-hoped approval of its flagship antidepressant Zurzuvae by the
Biogen and Sage Therapeutics' zuranolone has become the first oral drug to be approved by the FDA for post-partum depression (PPD), but the US regulator turned down a requ
In a new white paper from the World Without Disease initiative, a 2024 update is provided of the current endeavours and developments that have occurred since inaugural discussions last year